Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Eyes on Alzheimer’s: the promise of the retina in research and healthcare

The retina is often considered an extension of the brain, as they share many functional and structural similarities. Retinal changes…

Date: 20th December 2023

Exciting developments in microglia research in Alzheimer’s disease

Genetic studies have shown that the vast majority of risk genes for Alzheimer’s Disease (AD) are highly, or even preferentially,…

Date: 14th April 2023

Eyes on Alzheimer’s: the promise of the retina in research and healthcare

The retina is often considered an extension of the brain, as they share many functional and structural similarities. Retinal changes…

Date: 20th December 2023

Exciting developments in microglia research in Alzheimer’s disease

Genetic studies have shown that the vast majority of risk genes for Alzheimer’s Disease (AD) are highly, or even preferentially,…

Date: 14th April 2023

Expert perspectives on lecanemab

On January 6, 2023, the US Food and Drug Administration (FDA) approved lecanemab for the treatment of Alzheimer’s disease (AD),…

Date: 15th March 2023

Nutrition and cognitive decline

Cognitive decline caused by dementia is one of the leading causes of disability and dependency for older adults globally, and…

Date: 5th December 2022

Novel markers for Alzheimer’s disease monitoring and prognostication

Our current podcast series is focused on Alzheimer’s disease biomarkers. Hundreds of studies have emerged in recent years that have…

Date: 31st October 2022

Early biomarkers for Alzheimer’s disease

Blood biomarkers are taking off in the Alzheimer’s disease field, showing promise for diagnosis, prognostication, and treatment monitoring. As more…

Date: 7th October 2022

Alzheimer’s disease blood tests? Bringing plasma biomarkers into clinical practice

Blood biomarkers are taking off in the Alzheimer’s disease field, showing promise for diagnosis, prognostication, and treatment monitoring. Current diagnostic…

Date: 6th September 2022

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and tau

The complexity of Alzheimer’s disease (AD) pathogenesis has led to difficulties understanding the disease and, therefore, impacted the development of…

Date: 29th July 2022

Synaptic function in Alzheimer’s disease

Alzheimer’s disease (AD) is a neurodegenerative disorder predominately afflicting the older population – and with recent exponential developments in medicine…

Date: 15th June 2022

Novel developments in biomarkers for FTD

Frontotemporal dementia (FTD) occurs when nerve cells in the frontal and temporal lobes of the brain are lost, causing the…

Date: 7th April 2022

Therapeutic plasma exchange to slow cognitive decline in Alzheimer’s disease

Therapeutic plasma exchange (TPE) is used to treat a variety of neurological, immunological, and metabolic disorders. The procedure removes patient…

Date: 3rd February 2022

Recent advances in plasma biomarkers for Alzheimer’s disease

In recent years, blood-based biomarkers have taken off in the dementia space, representing a less invasive, more cost-effective, and accessible…

Date: 2nd February 2022